Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors

(2011) L. S. Rosen et al.   CLINICAL CANCER RESEARCH

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

(2011) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

(2010) Heounjeong Go et al.   Journal of Thoracic Oncology

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

(2009) Federico Cappuzzo et al.   JOURNAL OF CLINICAL ONCOLOGY

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

(2009) Michèle Beau-Faller et al.   Journal of Thoracic Oncology

In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue

(2009) Natalia Guzmán-Ramírez et al.   PROSTATE

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

(2008) F. Cappuzzo et al.   ANNALS OF ONCOLOGY

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

(2008) Z Tang et al.   BRITISH JOURNAL OF CANCER

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

Expression and mutational analysis ofMETin human solid cancers

(2008) Patrick C. Ma et al.   GENES CHROMOSOMES & CANCER

Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Chang-Qi Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY